Luca Santarelli, VectivBio CEO
March 30, 2022 10:07 AM EDTUpdated April 1, 03:06 PM
Financing

Lu­ca Santarel­li's Vec­tivBio bags $100M-plus in new fund­ing from li­cens­ing pact, loan

Paul Schloesser

Associate Editor

Lu­ca Santarel­li’s rare dis­ease play­er Vec­tivBio, just three years out from be­ing found­ed by the Roche vet and just a year af­ter go­ing pub­lic on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times